Michael G Agadjanyan
Works at
Sources: reporter.nih.gov
Grants and prizes
R01, FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants., R01AG092949, 2025–2030, 25 Aug 2026
U01, IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD), U01AG084528, 2024–2029, 10 Aug 2026
R01, Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA., R01AG074983, 2022–2027, 30 Jan 2026
Sources: reporter.nih.gov